NCT06273852View on ClinicalTrials.gov

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

March 15, 2025

Study Completion Date

March 31, 2025

Conditions
Head and Neck Squamous Cell CarcinomaSoft Tissue Sarcoma AdultTriple Negative Breast Cancer
Interventions
DRUG

PBA-0405

Intratumoral microdose injection by the CIVO device.

Trial Locations (4)

19107

University of Pennsylvania, Philadelphia

29406

Sarah Cannon Research Institute, Charleston

71115

LSU Health Sciences Center, Shreveport

97239

Oregon Health and Science University, Portland

Sponsors

Collaborators (1)

Presage Biosciences
All Listed Sponsors
collaborator

Presage Biosciences

INDUSTRY

lead

Pure Biologics S.A.

INDUSTRY

NCT06273852 - A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter